OTTAWA, May 24, 2016 /CNW/ - Canadians face wait times of about 449 days in order to get access to new, potentially lifesavingmedicines in public drug plans, according to a new IMS Health Canada Inc. report commissioned by Innovative Medicines Canada.
The 2016 Access to New Medicines in Public Drug Plans: Canada and Comparable Countries
Canadians who rely on public drug plans are facing more than a year's delay to access new, potentially lifesaving treatments. This report shines the light on why access to medicines in Canada needs to be improved – patients must come first.
"Compared to similar countries, Canadian patients have access to fewer new medicines and also face long delays for the drugs that are covered under public drug plans." – Brett Skinner, Executive Director, Health and Economic Policy, Innovative Medicines Canada
"Canada needs to get these life-altering innovations to patients faster and without delay – no excuses, just do it." – Larry Taylor, living with diabetes
ABOUT INNOVATIVE MEDICINES CANADA
Innovative Medicines Canada is the national voice of Canada's innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members' commitment to being valued partners in the Canadian healthcare system.
SOURCE Innovative Medicines Canada
Subscribe to our Free Newsletters!
Hand hygiene is a simple and affordable technique to prevent infections.
Erythropoietin is a hormone secreted by kidneys in response to low oxygen levels in tissues ...
Local anesthesia is a type of anesthesia generally used to block pain sensation only in a specific ...View All